Popinat, G., Cousse, S., Goldfarb, L., Becker, S., Gardin, I., Salaün, M., . . . Decazes, P. (2019). Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. Oncoimmunology.
Chicago ZitierstilPopinat, Geoffrey, et al. "Sub-cutaneous Fat Mass Measured On Multislice Computed Tomography of Pretreatment PET/CT Is a Prognostic Factor of Stage IV Non-small Cell Lung Cancer Treated By Nivolumab." Oncoimmunology 2019.
MLA ZitierstilPopinat, Geoffrey, et al. "Sub-cutaneous Fat Mass Measured On Multislice Computed Tomography of Pretreatment PET/CT Is a Prognostic Factor of Stage IV Non-small Cell Lung Cancer Treated By Nivolumab." Oncoimmunology 2019.